Analysis for RMD
- 📈 Growth — 24/30
- 💰 Profitability — 19/20
- 🏦 Financial Health — 18/20
- 💵 Valuation — 14/20
- ⚠️ Risk — 5/10
Overall Score: 80/100
Summary:
📈 Growth & Financial Trajectory
Over the eight quarters, Revenues grew from about $1.223B (2024Q4) to about $1.431B (2026Q3), a cumulative rise of roughly 17%. Net income rose from about $292.2M to $398.7M (+36%). Gross margin moved from about 58.6% to about 62.2%, and operating margin expanded from roughly 31% to 34.9%, signaling stronger operating leverage.
💰 Margins & Cash Flow
- Gross margin and operating margin improved across the period, reflecting scale and cost discipline.
- Cash flow remained robust: in 2026Q3, net cash flow from continuing operating activities was $554.1M, with continuing free cash flow around $241.0M after financing and investing. Net cash flow was positive in each quarter, supported by positive operating cash generation.
🛡️ Balance Sheet & Liquidity
- Equity attributable to parent: $6.492B; total assets: $8.864B; current assets: $4.064B vs current liabilities: $1.351B (current ratio ~3.0).
- Long-term debt: $404.2M; liabilities remain well-covered by equity, indicating solid liquidity and cushion.
⚠️ Key Drivers & Risks
- Drivers: (1) Demand for sleep/respiratory devices; (2) strong cash flow generation and margin expansion.
- Risks: (1) Healthcare reimbursement/regulatory shifts; (2) competitive/tech disruption and FX exposure.